Revenio is a global leader in ophthalmological devices. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure measurement devices under the iCare brand, retinal imaging devices and perimeters. The main tools for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).
In 2019, the Group's net sales totaled EUR 61.1 million, with its operating profit standing at 28.1%. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
Revenio has published its Annual Report for 2020
Q1 interim report will be published on April 23, 2021
CFO Robin Pulkkinen robin.pulkkinen(at)revenio.fi
Revenio is listed on Nasdaq Helsinki
Revenio is followed by Carnegie, Inderes, OP and SEB